Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Sees Significant Decrease in Short Interest

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 4,100 shares, a decrease of 39.7% from the January 31st total of 6,800 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily volume of 33,300 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 76.14% of the company’s stock.

Galmed Pharmaceuticals Price Performance

Shares of GLMD stock traded down $0.20 during trading hours on Monday, reaching $1.94. 26,332 shares of the company traded hands, compared to its average volume of 693,117. The company has a market cap of $1.25 million, a P/E ratio of -0.12 and a beta of 0.66. Galmed Pharmaceuticals has a 12-month low of $1.95 and a 12-month high of $23.80. The firm has a 50-day moving average price of $2.78 and a 200 day moving average price of $3.57.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Galmed Pharmaceuticals in a research note on Monday, February 24th. They set a “sell” rating for the company.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.